Year: 2026
Type: article
Abstract: We read with great interest the study by Su et al.¹ reporting clinical and immunologic outcomes of patients with primary membranous nephropathy treated with obinutuzumab.The authors should be commended for addressing an important and evolving therapeutic area.After careful review of Table 3, which details patients classified as non-responders, we would like to highlight several points that may merit further consideration.
Source: Kidney International Reports
Authors: İlker Atay, Erhan Eröz, Cihan Heybeli
Institution: Dokuz Eylül University
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,800
OpenAlex ID: W7119736522